Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
PrEP uptake was already low – and then came the cuts
Counting the costs of global HIV funding disruptions
Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals
Oropharyngeal cancer is becoming more common in heterosexual men with HIV
Statin treatment reduces blood pressure in people with HIV, REPRIEVE trial shows
French study confirms efficacy of on-demand PrEP
The war on science: resisting and rebuilding at a crucial juncture
CD8 cell fitness predicts who benefits most from antibody-based cure strategies
